HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by van Eijk, I C Articles by Simsek, S Search for Related Content PubMed PubMed Citation Articles by van Eijk, I C Articles by Simsek, S

Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis

¹ Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands, ² Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands, ³ Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands and ⁴ Department of Endocrinology/Diabetes Center, VU University Medical Center, PO Box 7057, 1007 MB, Boelelaan 1117, Amsterdam, The Netherlands

(Correspondence should be addressed to S Simsek; Email: Simsek{at}vumc.nl)

Abstract

Tumour necrosis factor (TNF) is a pro-inflammatory cytokine which has been closely linked to obesity and insulin resistance. We present two cases of patients with rheumatoid arthritis (RA) and concomitant diabetes mellitus, who showed a marked decrease of fructosamine levels after initiating therapy with adalimumab, a TNF-blocking agent, for active RA. This finding may implicate that TNF blockade causes better glycaemic control in RA patients with concomitant diabetes, possibly by improving insulin resistance.